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Abstract 
Purpose 
To investigate the mean changes over time in health-related quality of life among advanced cancer 
patients who did not receive any intervention: changes among all patients versus changes in 
subgroups of patients with high initial symptom scores. 
 
Methods 
Patients with advanced cancer answered two questionnaires, containing the EORTC QLQ-C30 (15 
multi- or single-item scales), with approximately one month in between and received no known 
intervention in the intervening period. 
 
For each QLQ-C30 scale we estimated the mean change among all patients and in subgroups of 
patients scoring at least 33%, 50% and 66%, respectively, of maximum scale-score in the first 
questionnaire. 
 
Results 
In total, 1,014 patients completed both questionnaires. As hypothesized, we found no change over 
time in mean scores when including all patients (average mean change=-0.9 (95% CI=-1.5;-0.6)). 
The subgroups of patients scoring at least 33%, 50% or 66% of maximum scale-score, the score 
changed towards lower scores with mean changes of -9.2 (95% CI=-10.1;-8.4), -13.1 (95% CI=-
14.4;-11.8), and -15.6 (95% CI=--17.2;-13.9), respectively. 
 
Conclusions 
We quantified the magnitude of change over a one month period in health-related quality of life in 
stable advanced cancer patients, and in sub-groups selected according to specific, initial symptom 
levels. This information may help the interpretation of longitudinal studies of patients selected via 
screening. 
  
   
Introduction 
Identifying patients who have symptoms and problems and who are therefore considered in need for 
additional service may enable appropriate referral and maximize effective utilization of e.g., 
psychosocial services, a view that is supported by clinical practice guidelines [1]. For example in 
trials of psychosocial interventions in cancer patients, studies have found that the largest 
improvements in psychological distress, cognitive impairment and quality of life can be expected 
among patients with high initial levels of distress [2]. 
 
Therefore, quite sensibly, trials investigating the effect of a psychosocial intervention may often 
wish to preselect patients, who the researchers believe may benefit from the intervention. Generally, 
a target population is first determined and then individuals with a level of distress above a certain 
threshold within that population are included. However, one might assume that when screening 
patients, and thereby grouping individuals according to their initial high level of distress, the 
patients may reach a more average level over time – even without an intervention. This may be 
because those with high initial distress have a greater opportunity to improve than individuals with 
less extreme scores. It may also be because symptoms and problems have a tendency to pass, 
because patients will seek treatment outside the intervention investigated due to their distress, or the 
high score may be an error, e.g., if the patient has selected the wrong response option.  
 
We could think of this potential change among patients with high initial scores as a regression 
towards the mean (RTM), although this is not the standard use of the term. RTM is the tendency for 
a variable that is extreme on its first measurement will tend to be closer to the average on its second 
measurement – and an observation that is extreme on its second measurement will tend to have been 
closer to the average on its first [3].  
 
To our knowledge, no papers have investigated the mean changes in symptoms and problems over 
time in advanced cancer patients with higher initial scores who did not receive an intervention. The 
purpose of this paper was therefore to empirically investigate this mean change over time (which 
could be thought of as a potential RTM) for subgroups of patients with different levels of levels of 
distress at first assessment.  
 
 
   
 
Our hypotheses were:  
1) The correlations between repeated measurements of symptoms or problems with a month in 
between are moderate to high when including all patients in the sample, indicating relatively 
minimal change in the measurements within subjects.   
2) The average level of symptoms and problems in a cross-sectional sample of cancer patients 
NOT receiving any intervention is not different one month later, indicating no mean change. 
3) There are substantial mean changes over time when including only patients having high initial 
scores. 
 
Method 
Patients  
The inclusion of patients has been described previously [3-4]. To achieve a random and 
representative sample we included patients from three out of 14 hospital regions across Denmark. 
From each participating department a random sample of cancer patients (selected based on date of 
birth) was included if patients: a) were at least 18 years, b) lived in the region, c) had been in 
contact with the hospital department within the previous year, d) had cancer (solid tumors or 
lymphomas stages 3 or 4 according to the TNM system[6]; cancer in the central nervous system and 
small cell lung cancer in any stage, or leukemia, e) spoke Danish, and f) did not have a cognitive 
impairment or a psychiatric co-morbidity. Eligible patients received a questionnaire and a letter 
including informed consent by mail. The study was approved by the local ethics committee (01-
116/03 and 11-143/03) and took place from October 2004 to January 2006.  
 
Design and intervention 
Patients received the first questionnaire at a random time that was not affected by their treatment 
status or their contact to the hospital. Approximately two weeks after the first questionnaire was 
received by the research coordinator, an additional questionnaire was sent to the patients. Between 
the first and the second questionnaire no intervention was initiated based on the study. Thus, we 
expected the same level of distress in the two assessments, as the patients were contacted at a 
random time unrelated to their treatment. 
 
 
   
 
Questionnaires 
The EORTC QLQ-C30 [6-7] was administered at both occasions. It assesses health-related quality 
of life and consists of nine multi-item scales measuring: physical function, role function, emotional 
function, cognitive function, social functioning, global health status/quality of life, fatigue, nausea 
and vomiting, and pain, and six single-item scales: dyspnoea, insomnia, lack of appetite, 
constipation, diarrhoea and financial difficulties. For symptoms scales a high score indicate more 
symptom (the higher the worse). For function scales a high score represent better functioning (the 
higher the better). 
   
Statistical analyses 
The data were analysed with SAS statistical software, version 9.4 [7]. 
 
The answers to the EORTC QLQ-C30 were converted to 0-100 scales according to the scoring 
manual [6-7].  
 
We estimated the intraclass correlation between the first and second questionnaire for each of the 15 
scales in the EORTC QLQ-C30 using the total sample. The interclass correlations coefficient is 
equivalent to the quadratic weighted kappa and a coefficient of 1 indicates maximum possible 
correlation, whereas a coefficient of 0 indicates no correlation [10]. 
 
We calculated the mean change over time for each of the 15 scales in the EORTC QLQ-C30. First, 
we did this including all patients who had answered the two questionnaires in order to test 
hypothesis 1. Second, we investigated the mean change for patients who had scored at least 33%, 
50% or 66%, respectively, of what corresponds to “maximum distress score” (for a symptom scale 
this corresponds to a score of 100, for a function scale and Global health status/QoL this 
corresponds to a score of 0) in the first questionnaire. A score of 33% corresponds to an average 
response of “a little” (symptom/problem) to the items in a scale, 50% is in the middle of the scale 
and 66% corresponds to “quite a bit” symptom/problem. 
 
 
 
   
Results 
Participants 
The first questionnaire was completed by 1,447 patients and 1,014 of these also completed the 
second questionnaire with a mean of 31 days in between (SD=15.5 days). Table 1 shows the 
baseline characteristics of the 1,014 patients who completed both questionnaires. 
 
(Table 1 approximately here) 
 
As hypothesized, when including all patients there was a moderate to high correlation between the 
first and second measurements of the 15 scales ranging from 0.55 (95% CI=0.48;0.62) to 0.89 (95% 
CI= 0.87;0.91) (table 2).  
 
(Table 2 approximately here) 
 
As hypothesized, there were very small changes over time in the 15 scales ranging from -1.9 to 2.1; 
the mean change across scales was -1.0 (95% CI=-1.5;-0.6) (Table 3). 
  
The mean change for increasing cut-off values is shown in Table 3. As hypothesized, there were 
substantial changes over time in patients with high initial scores. The mean change across all scales 
increased with higher cut-off threshold for initial scores from mean -9.2 (95% CI=-10.1;-8.4) for 
cut-off at least 33% to -15.6 (95% CI=-17.2;-13.9) for cut-off at least 66% of maximum score.  
 
(Table 3 approximately here) 
 
The largest change was observed for nausea/vomiting: -20.3 (95% CI=-24.9;-15.7), -29.4 (95% 
CI=-37.3;-21.5) and -37.9 (95% CI=-49.2;-26.7), for patients scoring at least 33%, 50% or 66% of 
maximum initial score (table 3), respectively. Figure 1 shows the distribution of scores for 
nausea/vomiting at the two assessments among patients scoring at least 33% of maximum score in 
the first questionnaire. Obviously, there are therefore no observations below 33 at the first 
assessment, and the histogram exemplifies how the level of symptoms is more evenly distributed at 
the second measurement.  
 
   
(Figure 1 approximately here) 
 
Among functional scales the largest change was for social functioning: 12.6 (95% CI=10.2;15.0), 
17.7 (95% CI=14.4;20.9) and 19.8 (95% CI=15.6;24.0) for patients initially scoring 33%, 50% or 
66% of maximum distress, respectively. 
 
Discussion 
The present study provides data supporting our three hypotheses of (1) moderate to high 
correlations between the first and second assessment of symptoms and problems, (2) no mean 
change over time in the total sample of advanced cancer patients, and (3) substantial changes over 
time in patients having high initial scores with larger changes for higher cut-points. We used data 
for change over time in the 15 scales of the EORTC QLQ-C30 from a large sample of presumably 
stable cancer patients. To the best of our knowledge this is the first study to empirically investigate 
the change over time in symptoms and problems, according to various cut-points, in advanced 
cancer patients, who did not receive an intervention. 
 
Our findings showed moderate to high correlations between the first and second measurements of 
symptom and problems and very small changes over time when including all patients in the 
analysis. This confirmed that, overall, patients were stable. However, when selecting patients with 
initial high levels of distress we found large mean changes. The largest change was found for 
nausea/vomiting with mean changes of -20.3 to -37.9. 
  
These findings can be interpreted as the hypothesised regression toward the mean (RTM). RTM has 
previously been reported in studies measuring blood pressure and cholesterol, where any two 
observations are rarely identical and higher initial values are likely to be followed by an observation 
closer to the person’s average value [9,10, 11].  
 
We believe that the mean changes found in this study cannot exclusively be viewed as a result of 
RTM in its traditional meaning, but could also be caused by a variety of reasons including placebo 
effects, patients seeking treatment on their own initiative, or patients simply getting accustomed to 
the distress. This illustrates that if patients with high initial scores are offered intervention, it may be 
   
difficult to distinguish a treatment effect from changes in symptoms and problems caused by other 
reasons than the intervention.  
 
A limitation of the study could be the missing data. Not all patients filled in the second 
questionnaire. It is possible that the patients who had the worst symptoms and problems at the 
second measurement did not answer the second questionnaire and this may bias the results. 
However, results are still applicable to the interpretation of other questionnaire studies where the 
same attrition is likely to occur.  
 
In conclusion, this study has produced estimates of the magnitude of mean changes for advanced 
cancer patients when subgroups having high initial scores are followed over a period of 
approximately one month. The findings contribute to the understanding of the dynamic nature of 
symptoms and problems, which is essential when interpreting results from clinical studies. Failure 
to acknowledge a mean change occurring as a result of preselecting patients with initially high 
levels of distress may lead to wrong conclusions if changes over time are solely interpreted as 
effects of intervention.  
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Table 1. Characteristics of the 1014 participants who had answered both questionnaires. 
Characteristics  N % 
No. of patients  1014  
Age, mean (SD)  62(13)  
Gender  
Male  466 56 
Female  548 54 
Primary tumour site Lung 58 6 
Head and neck 50 5 
Gynecological 74 7 
Prostate 68 7 
Breast 166 16 
Gastrointestinal 158 16 
Bladder 25 2 
Multiple myeloma 37 4 
Chronic myelogenous leukemia 24 2 
Chronic lymphocytic leukemia 85 8 
Acute myeloid leukemia 27 7 
Other 101 10 
Cancer stage Stage 3 343 34 
Stage 4 313 31 
Haematological  327 32 
Not applicable  31 3 
Diagnosis received 0-6 months 121 13 
6-12 months 130 14 
1-2 years 185 19 
2-5 years 168 18 
5-10 years 90 10 
>10 years 247 26 
Missing 73  
Contact type Hospitalized  106 11 
Out-patient  897 89 
Missing 8  
Department 
Surgical 315 31 
Oncological 339 34 
Medical 75 7 
Haematological 285 28 
 
Table 2. Mean EORTC QLQ-C30 scale scores for the first and second measurements (with a mean of 31 days in between) and their 
correlations and their 95% confidence intervals.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All scores range from 0-100. In function scales (role function, physical function, emotional function, social function and cognitive function) and Global health status/QoL a 
high score indicate better function. In symptom scales (fatigue, pain, nausea and vomiting, appetite loss, constipation, dyspnea, diarrhoea, financial problems and insomnia) a 
high score indicates more symptom.  
Symptom/problem N 
First measurement 
mean [95 % CI] 
Second measurement 
mean [95 % CI] 
Correlation 95 % CI 
Role function 985 68.9 [67.2;70.8] 61.1 [69.4.2;72.8] 0.79 0.76;0.82 
Physical function 996 77.1 [75.9;78.3] 77.1 [75.9;78.3] 0.89 0.87;0.91 
Emotional function 963 80.3 [79.2;81.5] 80.1 [79.7;81.9] 0.78 0.75;0.81 
Social function 962 81.4 [80.1;82.8] 83.5 [82.1;84.8] 0.69 0.64;0.74 
Cognitive function 967 81.8 [80.6;83.0] 82.4 [81.2;83.6] 0.78 0.78;0.82 
Fatigue 994 34.7 [34.2;37.2] 33.8 [32.4;35.3] 0.82 0.79;0.84 
Pain 1006 23.1 [21.6;24.6] 22.4 [20.9;23.9] 0.73 0.69;0.78 
Nausea and vomiting 993 7.1 [6.2;7.9] 6.5 [5.7;7.4] 0.54 0.45;0.62 
Appetite loss 992 14.4 [12.9;15.8] 13.0 [11.7;14.4] 0.67 0.61;0.73 
Constipation 959 10.5 [9.3;11.7] 10.4 [9.3;11.6] 0.67 0.61;0.74 
Dyspnea 983 17.6 [16.2;19.0] 16.3 [14.9;17.7] 0.72 0.67;0.77 
Diarrhoea 961 12.2 [11.0;13.4] 12.0 [10.8;13.2] 0.55 0.48;0.62 
Financial problems 959 10.4 [9.1;11.6] 9.7 [8.5;10.9] 0.70 0.64;0.76 
Insomnia 991 23.3 [21.8;24.9] 21.5 [20.1;23.0] 0.71 0.66;0.75 
Global health status/QoL 964 67.9 [66.6;69.2] 67.6 [66.3;68.9] 0.73 0.69;0.76 
Table 3. Mean difference in QLQ-C30 scales measured with a mean of 31 days in between for patients scoring at least what corresponds to 33%, 
50% and 67% of maximum distress, respectively, in the first questionnaire and all patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All scores range from 0-100. In function scales (role function, physical function, emotional function, social function and cognitive function) and QoL a high score indicate better function. In 
symptom scales (fatigue, pain, nausea and vomiting, appetite loss, constipation, dyspnea, diarrhoea, financial problems and insomnia) a high score indicates more symptom.  
a 
Calculated as mean difference between scores measured with the first questionnaire and the second questionnaire. A positive difference in the function scales indicates better function at the 
second measurement. A negative difference in the symptom scales indicates less symptom at the second measurement. 
b 
The average mean change was calculated as the sum of mean changes in all scales. All changes in the average mean was calculated as positive, e.g. high scores indicates more 
symptom/problem.  
Symptom/problem 
All patients Cut-off on 33% Cut-off on 50% Cut-off on 66% 
N 
Mean changea  
[95 % CI] 
N 
Mean changea  
[95 % CI] 
N 
Mean changea  
[95 % CI] 
N 
Mean changea   
[95 % CI] 
Role function 985 2.1 [0.9;3.2] 486 8.7 [6.8;10.5] 314 13.1 [10.7;15.5] 233 14.6 [11.8;17.4] 
Physical function 985 0.0 [-0.5;0.6] 315 2.7 [1.3;3.9] 149 4.9 [2.8;6.9] 70 5.9 [8.6;17.6] 
Emotional function 963 0.5 [-0.3;1.3] 273 7.1 [5.2;9.0] 127 11.3 [8.4;14.2] 57 13.1 [8.6;17.6] 
Social function 962 2.0 [0.9;3.1] 299 12.6 [10.2;15.0] 170 17.7 [14.4;20.9] 96 19.8 [15.6;24.0] 
Cognitive function 967 0.6 [-0.2;1.3] 285 7.7 [5.8;9.6] 134 10.9 [7.8;14.1] 75 11.1 [6.9;15.3] 
Fatigue 994 -1.9 [-2.8;-0.9] 551 -5.9 [-7.3;-4.6] 291 -9.6 [-11.6;-7.6] 210 -16.8 [-13.4;-8.6] 
Pain 1006 -0.6 [-1.7;0.5] 369 -10.3 [-12.4;-8.1] 238 -14.6 [-17.3;-11.9] 154 -16.8 [-20.3;-13.2] 
Nausea and vomiting 993 -0.5 [-1.4;0.3] 106 -20.3 [-24.9;-15.7] 51 -29.4 [-37.3;-21.5] 29 -37.9 [-49.2;-26.7] 
Appetite loss 992 -1.4 [-2.5;-0.3] 259 -16.4 [-19.7;-13.3] 124 -25.0 [-30.3;-19.7] 124 -25.0 [-30.3;-19.7] 
Constipation 959 -0.0 [-1.0;0.9] 211 -12.2 [-15.3;-8.9] 68 -21.1 [-27.9;14.2] 68 -21.1 [-27.9;-14.2] 
Dyspnea 983 -1.3 [-2.3;-0.3] 360 -10.6 [-12.8;-8.5] 123 -20.1 [-24.1;-15.9] 123 -20.9 [-24.1;-15.9] 
Diarrhoea 961 -0.2 [-1.4;0.9] 260 -15.8 [-18.5;-13.1] 75 -24.4 [-30.4;-18.5] 75 -24.4 [-30.3;-18.5] 
Financial problems 959 -0.6 [-1.6;0.3] 191 -15.8 [-19.0;-12.4] 78 -20.9 [-27.0;-14.9] 78 -20.9 [-27.0;-14.9] 
Insomnia 991 -1.8 [-2.9;-0.6] 463 -11.1 [-13.1;9.1] 167 -19.2 [-22.8;-15.5] 167 -19.2 [-22.8;-15.5] 
QoL 964 -0.3 [-0.2;0.7] 490 4.1 [2.6;5.6] 287 8.7 [6.7;10.6] 126 16.7 [13.8;19.7] 
Average mean changeb 1008 -0.9 [-1.5;-0.6] 838 -9.2 [-10.1;-8.4] 561 -13.1 [-14.4;-11.8] 474 -15.6 [-17.2;-13.9] 
Figure 1. Nausea/vomiting scores as measured by the first and second questionnaire for patients scoring at least 33 in the first 
questionnaire. Scores range from 0-100 with a high score indicating a high level of nausea/vomiting. 
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